➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Mallinckrodt
McKesson
Boehringer Ingelheim
Dow

Last Updated: July 13, 2020

DrugPatentWatch Database Preview

COMTAN Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Comtan patents expire, and what generic alternatives are available?

Comtan is a drug marketed by Orion Pharma and is included in one NDA.

The generic ingredient in COMTAN is entacapone. There are twenty drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the entacapone profile page.

US ANDA Litigation and Generic Entry Outlook for Comtan

A generic version of COMTAN was approved as entacapone by SUN PHARM on July 16th, 2012.

  Start Trial

Drug patent expirations by year for COMTAN
Drug Prices for COMTAN

See drug prices for COMTAN

Recent Clinical Trials for COMTAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Daniel ClaassenPhase 1
Xiangya Hospital of Central South UniversityEarly Phase 1
Portland VA Medical CenterPhase 0

See all COMTAN clinical trials

Pharmacology for COMTAN
Paragraph IV (Patent) Challenges for COMTAN
Tradename Dosage Ingredient NDA Submissiondate
COMTAN TABLET;ORAL entacapone 020796 2007-04-11

US Patents and Regulatory Information for COMTAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Orion Pharma COMTAN entacapone TABLET;ORAL 020796-001 Oct 19, 1999 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for COMTAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Orion Pharma COMTAN entacapone TABLET;ORAL 020796-001 Oct 19, 1999   Start Trial   Start Trial
Orion Pharma COMTAN entacapone TABLET;ORAL 020796-001 Oct 19, 1999   Start Trial   Start Trial
Orion Pharma COMTAN entacapone TABLET;ORAL 020796-001 Oct 19, 1999   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for COMTAN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0426468 C00426468/01 Switzerland   Start Trial FORMER REPRESENTATIVE: BOHEST AG, CH
0426468 CA 2004 00007 Denmark   Start Trial
0426468 0490007-2 Sweden   Start Trial PRODUCT NAME: (E)-2-CYANO-N,N-DIETYL-3-(3,4-DIHYDROXI-5-NITROFENYL)AKRYLAMID; REGSISTRATION NO/DATE: EU/1/03/260/001 20031017
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Mallinckrodt
McKesson
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.